Liquidia Corp (LQDA)
12.70
-0.04
(-0.31%)
USD |
NASDAQ |
May 17, 16:00
12.70
0.00 (0.00%)
After-Hours: 20:00
Liquidia SG&A Expense (Quarterly): 20.25M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.25M |
| December 31, 2023 | 17.14M |
| September 30, 2023 | 10.56M |
| June 30, 2023 | 9.245M |
| March 31, 2023 | 7.793M |
| December 31, 2022 | 6.187M |
| September 30, 2022 | 6.744M |
| June 30, 2022 | 6.938M |
| March 31, 2022 | 12.54M |
| December 31, 2021 | 8.47M |
| September 30, 2021 | 4.882M |
| June 30, 2021 | 4.421M |
| March 31, 2021 | 5.337M |
| December 31, 2020 | 11.17M |
| September 30, 2020 | 7.152M |
| Date | Value |
|---|---|
| June 30, 2020 | 5.226M |
| March 31, 2020 | 3.823M |
| December 31, 2019 | 5.789M |
| September 30, 2019 | 2.378M |
| June 30, 2019 | 2.409M |
| March 31, 2019 | 3.022M |
| December 31, 2018 | 2.329M |
| September 30, 2018 | 2.284M |
| June 30, 2018 | 1.991M |
| March 31, 2018 | 2.150M |
| December 31, 2017 | 2.134M |
| September 30, 2017 | 3.005M |
| June 30, 2017 | 2.924M |
| March 31, 2017 | 2.151M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.378M
Minimum
Sep 2019
20.25M
Maximum
Mar 2024
7.923M
Average
6.841M
Median
SG&A Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 144.40M |
| AIM ImmunoTech Inc | 10.86M |
| Perspective Therapeutics Inc | 5.878M |
| Protalix BioTherapeutics Inc | 3.115M |
| Armata Pharmaceuticals Inc | 3.178M |